α-Melanocyte-Stimulating Hormonelike Immunoreactivity Is Increased in Cerebrospinal Fluid of Patients With Parkinson's Disease

Archives of Neurology

Volumn 45, Issue 11, 1988, Pages 1224-1227

  Rainero, Innocenzo ^a   Kaye, Jeffrey A ^a,c   May, Conrad ^a   Durso, Raymon ^b   Katz, Douglas I ^b   Albert, Martin L ^b   Wolfe, Nicola ^b   Pinessi, L ^a   Friedland, R P ^a   Rapoport, Stanley I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; PROOPIOMELANOCORTIN;

ADULT; AGE; AGED; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; ALPHA-MSH; FEMALE; HUMAN; MALE; MIDDLE AGE; PARKINSON DISEASE;

EID: 0023757123     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.1988.00520350062017     Document Type: Article

References (47)

1. 1. O'Donohue TL, Dorsa DM: The opiomelanotropinergic neuronal and endocrine systems. Peptides 1982;3:353-395.
2. 2. Khachaturian H, Lewis ME, Tsou K, et al: β-Endorphin, α-MSH, ACTH and related peptides, in Bjorklund A, Hokfelt T (eds): Handbook of Chemical Neuroanatomy. New York, Elsevier Science Publishing Co Inc, 1985, pp 216-272.
3. 3. O'Donohue TL, Jacobowitz DM: Studies on α-melanotropin in the central nervous system, in Beers RF, Bassett EG (eds): Polypeptide Hormones. New York, Raven Press, 1980, pp 203-222.
4. 4. O'Donohue TL, Miller RL, Jacobowitz DM: Identification, characterization and stereotaxic mapping of intraneuronal α-melanocyte stimulating hormone-like immunoreactive peptides in discrete regions of the rat brain. Brain Res 1979;176:101-123.
5. 5. Watson SJ, Akil H: Alpha-MSH in rat brain: Occurrence within and outside brain betaendorphin neurons. Brain Res 1980;182:217-223.
6. 6. Khachaturian H, Akil H, Browstein MJ, et al: Further characterization of the extra-arcuate alpha-melanocyte stimulating hormone-like material in hypothalamus: Biochemical and anatomical studies. Neuropeptides 1986;7:291-313.
7. 7. Barnea A, Neaves WB, Cho G, et al: A subcellular pool of osmotically resistant particles containing thyrotropin releasing hormone, alpha-melanocyte stimulatinghormone and luteinizing hormone releasing hormone in the rat hypothalamus. J Neurochem 1978;30:937-948.
8. 8. Dunn AJ, Green EJ, Issacson RL: Intracerebral adrenocorticotropic hormone mediates novelty-induced grooming in the rat. Science 1974;203:281-283.
9. 9. De Wied D: Influence of anterior pituitary on avoidance learning and escape behavior. Am J Physiol 1964;207:255-259.
10. 10. Jacquet YF, Abrams GM: Postural asymmetry and movement disorder after unilateral microinjection of adrenocorticotropin 1-24 in rat brainstem. Science 1982;218:175-177.
11. 11. Bertolini A, Vergoni W, Gessa GL, et al: Induction of sexual excitement by the action of adrenocorticotrophic hormone in brain. Nature 1969;221:667-669.
12. 12. Glun JR, Lipton JM: Hypothermic and antipyretic effects of centrally administered ACTH (1-24) and α-melanotropin. Peptides 1981;2:177-188.
13. 13. Shuster S, Thody AJ, Goolamali SK, et al: Melanocyte-stimulating hormone and parkinsonism. Lancet 1973;1:463-465.
14. 14. Kastin AJ, Barbeau A: Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease. Can Med Assoc J 1972;107:1079-1081.
15. 15. Chase TN, Woods AC, Lipton MA, et al: Hypothalamic releasing factors and Parkinson's disease. Arch Neurol 1974;31:55-56.
16. 16. Pique L, Jegou S, Bertagna X, et al: Proopiomelanocortin peptides in the human hypothalamus: Comparative studies between normal subjects and Parkinson patients. Neurosci Lett 1985;54:141-146.
17. 17. De Rotte AA, Bouman HJ, van Wimersma-Greidanus TB: Relationship between alpha-MSH levels in blood and in cerebrospinal fluid. Brain Res Bull 1979;5:375-381.
18. 18. Thody A, De Rotte AA, van Wimersma-Greidanus TB: Plasma and cerebrospinal fluid α-MSH secretion. Brain Res Bull 1979;4:213-216.
19. 19. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression and mortality. Neurology 1967;17:427-442.
20. 20. Duvoisin RC: The evaluation of extrapyramidal disease, in Ajuriagerra J (ed): Monoamines, Noyaux Gris Centraux de Parkinson. New York, Masson Publishers USA Inc, 1970, pp 313-325.
21. 21. American Psychiatric Association Task Force on Nomenclature and Statistics: Diagnostic and Statistical Manual of Mental Disorders (DSM-III), ed 3. Washington, DC, American Psychiatric Association, 1980, pp 124-126.
22. 22. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
23. 23. Duara R, Margolin RA, Robertson-Tchabo EA, et al: Cerebral glucose utilization as measured with positron emission tomography in 21 resting healthy men between the ages of 21 and 83 years. Brain 1983;106:761-775.
24. 24. Duara R, Grady C, Haxby J, et al: Human brain glucose utilization and cognitive function in relation to age. Ann Neurol 1984;16:702-713.
25. 25. Nappi G, Petraglia F, Martignoni E, et al: β-Endorphin cerebrospinal fluid decrease in untreated parkinsonian patients. Neurology 1985;35:1371-1374.
26. 26. Gross M, Bannister R, Gadwin-Austin R: Orthostatic hypotension in Parkinson's disease. Lancet 1972;1:174-176.
27. 27. Gubbay SS, Barwick DD: Two cases of accidental hypothermia in Parkinson's disease with unusual EEG findings. J Neurol Neurosurg Psychiatry 1966;29:459-466.
28. 28. Burton JL, Shuster S: Effect of L-DOPA on seborrhoea of parkinsonism. Lancet 1970;2:19-23.
29. 29. Malarkey WB, Cyrus J, Paulson GW: Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-DOPA therapy. J Clin Endocrinol Metab 1974;39:229-235.
30. 30. Lipman IJ, Boykin ME, Flora RE: Glucose intolerance in Parkinson's disease. J Chronic Dis 1974;27:573-579.
31. 31. Ohama E, Ikuta F: Parkinson's disease: Distribution of Lewy bodies and monoamine neuron systems. Acta Neuropathol 1976;34:311-319.
32. 32. Langston JW, Forno LS: The hypothalamus in Parkinson's disease. Ann Neurol 1978;3:129-133.
33. 33. Delanoy RL, Kramarcy NR, Dunn AJ: ACTH (1-24) and lysine vasopressin selectively activate dopamine synthesis in frontal cortex. Brain Res 1982;231:117-119.
34. 34. Torre E, Celis ME: α-MSH and MIF-I influence dopamine (DA) uptake on crude synaptosomal preparations from rat mediobasal hypothalamus (MBH) and caudate putamen (CP). Peptides 1984;5:669-674.
35. 35. Dunn AJ, Iuvone PM, Reas HD: Neurochemical response of mice to ACTH and lysine vasopressin. Pharmacol Biochem Behav 1976;5:139-145.
36. 36. Lichtensteiger W, Lienhart R, Kopp HG: Peptide hormones and central dopamine neuron systems. Psychoneuroendocrinology 1977;2:237-248.
37. 37. Wiegant WM, Colls AR, Gispen VH: ACTH-induced grooming involves brain dopamine. Eur J Pharmacol 1977;41:343-345.
38. 38. O'Donohue TL, Charlton CG, Thoa NB, et al: Release of alpha-melanocyte stimulating hormone into rat and human cerebrospinal fluid in vivo and from rat hypothalamic slices in vitro. Peptides 1981;2:93-100.
39. 39. Warberg J, Oliver C, Barnea A, et al: Release of immunoreactive alpha-MSH by synaptosome-enriched fractions of homogenates of hypothalami. Brain Res 1979;175:247-257.
40. 40. Locatelli V, Petraglia F, Penalva A, et al: Effect of dopaminergic drugs on hypothalamic and pituitary immunoreactive β-endorphin concentrations in the rat. Life Sci 1983;33:1711-1717.
41. 41. Ham J, Smyth DG: β-Endorphin processing in pituitary and brain is sensitive to haloperidol stimulation. Neuropeptides 1985;5:497-500.
42. 42. Millington WR, Maiewski S, O'Donohue TL, et al: Long-term haloperidol treatment elevates β-endorphin levels in the intermediate pituitary but not in rat brain. Neuropeptides 1985;6:365-372.
43. 43. Beal MF, Fisher J, Carr DB, et al: Effects of neuroleptic drugs on brain β-endorphin immunoreactivity. Neurosci Lett 1985;53:173-178.
44. 44. Tilders FJH, Smelik PG: Direct neural control of MSH secretion: The involvement of dopaminergic tubero-hypophyseal neurones, in Tilders F, Swaab D, van Wimersma-Greidanus TJ (eds): Frontiers in Hormone Research. New York, S Karger AG, 1977, vol 4, pp 80-95.
45. 45. Javoy-Agid F, Ruberg M, Pique L, et al: Biochemistry of the hypothalamus in Parkinson's disease. Neurology 1984;34:672-675.
46. 46. Baker H, Ruggiero DA, Alden S, et al: Anatomical evidences for interactions between catecholamine and adrenocrticotropin-containing neurons. Neurosci 1986;17:469-484.
47. 47. O'Donohue TL, Handelman GE, Chaconas T, et al: Evidence that N-acetylation regulates behavioral activity of α-MSH in the rat and human central nervous systems. Peptides 1981;2:333-344.